Diagnostics News and Research

RSS

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets. The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

10 Jun 2013

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced 10 new or updated software packages to help customers harness the power of its new-generation liquid chromatography-mass spectrometry (LC-MS) instruments and turn data into knowledge in a wide range of discovery and quantitation experiments.

From Thermo Fisher Scientific Inc. 10 Jun 2013

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system, combining its three mass analyzers –quadrupole, Orbitrap and linear ion trap – in a novel “Tribrid” architecture that offers unprecedented depth of analysis of complex biological samples.

From Thermo Fisher Scientific Inc. 10 Jun 2013

Exact Sciences announces submission of final module of PMA application to FDA for Cologuard

Exact Sciences Corp. today announced that it has submitted to the U.S. Food and Drug Administration the final module of the premarket approval application for Cologuard, the company's stool DNA (sDNA) colorectal cancer screening test.

10 Jun 2013

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene in tissues and blood sera.

10 Jun 2013

International experts formulate guidance for neuromodulation practitioners

An international panel of experts has formulated guidance for neuromodulation practitioners that reflects increasing recognition of the value of this growing field.

10 Jun 2013

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

The European Technology Platform on Nanomedicine and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

7 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives CE IVD Mark

BioFire Diagnostics, Inc. announced today that it obtained the CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices for its FilmArray Blood Culture Identification Panel.

6 Jun 2013

Sustained engagement, partnership needed to implement new treatments for neglected diseases

Days after two landmark resolutions were adopted at the World Health Assembly - on neglected tropical diseases and on research and development, financing and coordination for the health needs of developing countries - over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade.

6 Jun 2013

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.

4 Jun 2013

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.

4 Jun 2013

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Baylor Endocrine Center is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. The project is called the GRADE: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Duke Medicine, UCSF investigators to oversee research program on antibacterial resistance

Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.

4 Jun 2013

Allenex to sell its holding in AnaMar AB to Koncentra Holding

Allenex has agreed to sell its holding in AnaMar AB to the company's main owner Koncentra Holding. The price is set to 1,7 mkr. Allenex became an owner in AnaMar 1998.

3 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

EKF Diagnostics launches rapid strip-based test for hemoglobin at ISBT

EKF, has announced the global launch of a new strip-based test for quick and easy hemoglobin analysis for anemia determination.

From EKF Diagnostics 3 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Study shows utility of cfDNA blood tests for breast cancer patients

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center today announced that results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients are to be reported in a poster presentation titled "Modulation of breast cancer cell-free DNA with surgical resection" (Abstract #11060) at the American Society of Clinical Oncology Annual Meeting (ASCO 2013) being held from May 31 through June 4, 2013 in Chicago. The blood test detects cfDNA that is released into the blood stream by damaged and dying cancer cells.

1 Jun 2013

Diagnostics News and Research

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

Exact Sciences announces submission of final module of PMA application to FDA for Cologuard

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

International experts formulate guidance for neuromodulation practitioners

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

Diagnoplex secures 1.3 million Swiss francs from financing round

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives CE IVD Mark

Sustained engagement, partnership needed to implement new treatments for neglected diseases

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Baylor Endocrine Center seeks volunteers to compare long-term benefits and risks of diabetes drugs

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Duke Medicine, UCSF investigators to oversee research program on antibacterial resistance

Allenex to sell its holding in AnaMar AB to Koncentra Holding

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

EKF Diagnostics launches rapid strip-based test for hemoglobin at ISBT

Study finds HER2 irregularities in 14 different advanced solid tumors

Study shows utility of cfDNA blood tests for breast cancer patients

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News